Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons
- 24 March 2010
- journal article
- perspective
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 28 (4) , 365-383
Abstract
Bisphosphonates (BPs) have been widely, efficiently, and safely used for the treatment of osteoporosis, malignant hypercalcemia, bone metastasis of solid cancers, and multiple myeloma bone diseases. Accumulating recent reports describe that surgical dental treatments in patients with cancer or osteoporosis who have been receiving intravenous or oral BPs are associated with osteonecrosis of the jaw (bisphosphonate-related osteonecrosis of the jaw, BRONJ). The accurate incidence, clinical backgrounds, and pathogenesis of BRONJ have been unclear and appropriate approaches for prevention and treatment have not been established to date. To address the current situation of BRONJ in Japan, the “Allied Task Force Committee of Bisphosphonate-Related Osteonecrosis of the Jaw,” consisting of physicians specializing in bone biology, orthopedic surgery, rheumatology, obstetrics/gynecology, and medical oncology and dentists specializing in oral surgery, periodontology, dental radiology, and oral pathology, was organized. The committee attempted to propose a standard position paper for the treatment of BRONJ. The committee expects that this proposal will provide objective and correct scientific information on BRONJ and will serve as a reference for conducting dental procedures for patients receiving BPs and in designing prevention and treatment of BRONJ. However, because this position paper is not based on direct clinical evidence, it should be used as a reference, and a decision on treatment in each case should be made after an extensive discussion among physicians, dentists/oral surgeons, and the patients.Keywords
This publication has 101 references indexed in Scilit:
- Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: An analysis of 31 cases with confocal laser scanning microscopyBone, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Tooth Extraction Socket Healing in Pediatric Patients Treated with Intravenous PamidronateThe Journal of Pediatrics, 2008
- Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous BisphosphonatesJournal of Bone and Mineral Research, 2008
- Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holidayOsteoporosis International, 2008
- Mandible Matrix Necrosis in Beagle Dogs After 3 Years of Daily Oral Bisphosphonate TreatmentJournal of Oral and Maxillofacial Surgery, 2008
- Inhibition of Oral Mucosal Cell Wound Healing by BisphosphonatesJournal of Oral and Maxillofacial Surgery, 2008
- Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control StudyJournal of Oral and Maxillofacial Surgery, 2008
- Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?Bone, 2007
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005